PAMG-1与fFN试验对有症状孕妇急诊产科就诊后自发性早产风险的预测性能:回顾性队列研究
该回顾性队列研究比较了PAMG-1与fFN试验对急诊产科就诊的先兆早产孕妇自发性早产的预测性能。结果显示,fFN阳性率高于PAMG-1,但PAMG-1阳性预测 imminent 早产的可靠性是fFN的4倍以上,且两者对14天内自发性早产的排除效果无差异。
要点
- 对于有症状的先兆早产孕妇,PAMG-1试验阳性预测7天内自发性早产的阳性预测值为35.3%,fFN为7.9%。
- PAMG-1试验的阳性似然比为16.1,fFN为3.2,PAMG-1阳性结果对近期早产的预测可靠性更高。
- 两种试验对14天内自发性早产的排除效果(阴性预测值)相近,PAMG-1为98.3%,fFN为97.9%。
核心结论
- 在改用PAMG-1之前,fFN是自发性早产风险评估的标准生化试验;本回顾性审计显示,fFN试验阳性率是PAMG-1的两倍以上,但14天内自发性早产孕妇的出院率未受影响。
- PAMG-1试验阳性预测 imminent 自发性早产的可靠性是fFN试验的4倍以上。
- 使用更可靠、假阳性结果更少的生物标志物可能减少不必要的入院、干预和医院资源使用。
研究设计与样本
- 基于电子病历的回顾性队列研究,纳入两家独立1年期间(2012年基线期使用fFN,2016年比较期使用PAMG-1)因先兆早产就诊于三级产科医院的孕妇。
- 纳入标准:单胎妊娠,孕24+0至34+6周,有早产症状,胎膜完整,宫颈扩张<3 cm,且未在检测后14天内因医学指征早产。
- 基线期共420例先兆早产孕妇,378例(90.0%)符合纳入标准;比较期共410例,367例(89.5%)符合纳入标准。
主要发现
- 基线期fFN阳性38例(10.1%),7天内自发性早产10例(2.6%);fFN预测7天内自发性早产的阳性预测值7.9%、阴性预测值97.9%、阳性似然比3.2、阴性似然比0.8。
- 比较期PAMG-1阳性17例(4.6%),7天内自发性早产12例(3.3%);PAMG-1预测7天内自发性早产的阳性预测值35.3%、阴性预测值98.3%、阳性似然比16.1、阴性似然比0.5。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the performance of the placental alpha microglobulin-1 (PAMG-1) and fetal fibronectin (fFN) tests for the prediction of spontaneous preterm delivery in patients presenting to an emergency obstetric unit with threatened preterm labor, by conducting a retrospective audit of patient medical records from separate 1-year periods during which either fFN or PAMG-1 was used as the standard-of-care biochemical test. METHODS: This was a retrospective cohort study based on chart review of electronic medical records of women with threatened preterm labor presenting at a level-III maternity hospital over two different periods: (1) the 'baseline' period (year 2012), during which the qualitative fFN test with a cut-off of 50 ng/mL was used as the standard-of-care biochemical test for the risk assessment of preterm delivery, and (2) the 'comparative' period (year 2016), during which the PAMG-1 test with a cut-off of 1 ng/mL was used as the standard-of-care biomarker test. Patients with a singleton pregnancy between 24 + 0 and 34 + 6 weeks' gestation with symptoms of early preterm labor, clinically intact membranes and cervical dilatation < 3 cm, who did not have a medically indicated preterm delivery within 14 days of testing, were selected for chart review and included in the analysis. Key parameters used for the analysis were biochemical test results, time of testing and time of delivery. Positive predictive value (PPV), negative predictive value (NPV), sensitivity, specificity, and positive and negative likelihood ratios (LR+ and LR-) for the prediction of spontaneous preterm delivery ≤ 7 and ≤ 14 days of presentation were calculated for the PAMG-1 and fFN tests. RESULTS: Four hundred and twenty patients were identified as having presented with threatened preterm labor during the baseline period, of whom 378 (90.0%) met the eligibility criteria. Of these, 38 (10.1%) were fFN positive and 10 (2.6%) had spontaneous preterm delivery ≤ 7 days of presentation. PPV, NPV, LR+ and LR- of fFN were 7.9%, 97.9%, 3.2 and 0.8, respectively, for spontaneous preterm delivery ≤ 7 days. Four hundred and ten patients were identified as having presented with threatened preterm labor during the comparative period and 367 (89.5%) subjects met the eligibility criteria. Of these, 17 (4.6%) were PAMG-1 positive and 12 (3.3%) had spontaneous preterm delivery ≤ 7 days of presentation. PAMG-1 PPV and NPV were 35.3% and 98.3%, respectively, and LR+ and LR- were 16.1 and 0.5, respectively, for spontaneous preterm delivery ≤ 7 days. CONCLUSIONS: Before switching to PAMG-1, fFN was the standard-of-care test for the risk assessment of spontaneous preterm delivery. This retrospective audit of each test's performance over separate 1-year periods shows that we were more than twice as likely to get a positive fFN test than a positive PAMG-1 test, while the rate of discharging women who ultimately delivered spontaneously within 14 days of testing was not affected. Furthermore, a positive PAMG-1 test was more than four times more reliable than a positive fFN test in predicting imminent spontaneous preterm delivery. The use of a more reliable biomarker that is associated with fewer false-positive results could lead to a reduction in unnecessary admissions, interventions and use of hospital resources. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Melchor JC, Navas H, Marcos M, et al. Predictive performance of PAMG-1 vs fFN test for risk of spontaneous preterm birth in symptomatic women attending an emergency obstetric unit: retrospective cohort study. Ultrasound Obstet Gynecol. 2018. PMID: 28850753. doi:10.1002/uog.18892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。